Mark Chang, PhD, is the founder of AGInception and has more than 25 years of experience as a statistician in biopharmaceutical firms and CROs. He held various positions such as Senior Vice President of Strategic Statistical Consulting at Veristat, Vice President at AMAG Pharmaceuticals, and Scientific Fellow and Director at Takeda Pharmaceuticals. Dr. Chang is skilled in NDA submissions and has worked collaboratively with regulatory agencies throughout the clinical trial and submission process. Furthermore, he is an adaptive design expert and has extensive knowledge in AI for clinical trials. He has published 12 books on artificial intelligence & machine learning, adaptive clinical trial designs, biostatistics, and scientific principles. Dr. Chang is a fellow of the American Statistical Association and an adjunct professor of Biostatistics at Boston University. He is also a co-founder of the International Society for Biopharmaceutical Statistics and served as co-chair of the Biotechnology Industry Organization (BIO) Adaptive Design Working Group, as well as a member of the Multiregional Clinical Trial (MRCT) Expert Group. Dr. Chang earned his Ph.D. in Civil Engineering and his Master of Science in Biostatistics from the University of Massachusetts in Amherst, MA.